Exploratory analysis of interleukin-38 in hospitalized COVID-19 patients.

Dennis M De GraafLisa U TeufelAline H de NooijerAdriaan J van GammerenAntonius A M ErmensIldikó O GaálTania O CrișanFrank L van de VeerdonkMihai G NeteaCharles A DinarelloLeo A B JoostenRob J W Artsnull null

Published in: Immunity, inflammation and disease (2022)

These data indicate that IL-38 is not associated with disease outcomes in hospitalized COVID-19 patients. However, moderate correlations between IL-38 concentrations and biomarkers of disease were identified in one of two cohorts. While we demonstrate that IL-38 concentrations are not indicative of COVID-19 severity, its anti-inflammatory effects may reduce COVID-19 severity and should be experimentally investigated.

Keyphrases

sars cov
coronavirus disease
respiratory syndrome coronavirus
electronic health record
type diabetes
big data
deep learning
metabolic syndrome
atomic force microscopy
weight loss
glycemic control
single molecule